Correction to: Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022.

MLA

Yanagita, Motoko, et al. “Correction to: Clinical Questions and Good Practice Statements of Clinical Practice Guidelines for Management of Kidney Injury during Anticancer Drug Therapy 2022.” Clinical and Experimental Nephrology, vol. 28, no. 2, Feb. 2024, pp. 123–24. EBSCOhost, https://doi.org/10.1007/s10157-023-02436-9.

APA

Yanagita, M., Muto, S., Nishiyama, H., Ando, Y., Hirata, S., Doi, K., Fujiwara, Y., Hanafusa, N., Hatta, T., Hoshino, J., Ichioka, S., Inoue, T., Ishikura, K., Kato, T., Kitamura, H., Kobayashi, Y., Koizumi, Y., Kondoh, C., Matsubara, T., … Kashihara, N. (2024). Correction to: Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022. Clinical and Experimental Nephrology, 28(2), 123–124. https://doi.org/10.1007/s10157-023-02436-9

Chicago

Yanagita, Motoko, Satoru Muto, Hiroyuki Nishiyama, Yuichi Ando, Sumio Hirata, Kent Doi, Yutaka Fujiwara, et al. 2024. “Correction to: Clinical Questions and Good Practice Statements of Clinical Practice Guidelines for Management of Kidney Injury during Anticancer Drug Therapy 2022.” Clinical and Experimental Nephrology 28 (2): 123–24. doi:10.1007/s10157-023-02436-9.